retatrutide phase 2 nejm 2023 obesity trial results Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks SURPASS-2 (NEJM 2021) was the
Pay in 4 interest-free payments of $5.15 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28



.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)




.png)













